Axis Imaging The Script
The Script · Published by Axis Imaging, Melbourne

Saturday 14 November 2026

3 stories today

1. Q-VAX is down to a few hundred doses until 2027

A few hundred doses. That's how much Q-VAX Australia has left, according to manufacturer CSL Seqirus, and the company says normal supply is unlikely to return until 2027.

Spread across an entire country, a few hundred doses is less a stockpile than a rumour.

CSL Seqirus puts the shortfall down to manufacturing setbacks. Beyond that, details are thin. The report doesn't say what went wrong at the plant, how the remaining doses will be allocated, or whether any stopgap is on the way. The full article sits behind a paywall, so that's everything on the public record for now.

If you vaccinate at-risk rural workers, your supply has just shrunk to almost nothing for the foreseeable future. Patients who planned to get protected before starting new work will need to hear that the wait could run well into 2027. They should hear it from you before they find out at the front desk.

The other risk is wasted effort. Booking someone in, only to discover no dose is coming, burns an appointment and the patient's goodwill.

The takeaway: Before you book anyone for Q fever vaccination, confirm with your supplier that a dose actually exists. Tell at-risk patients now that normal supply isn't expected until 2027, and watch for any word from CSL Seqirus on how the last few hundred doses will be shared out.

Read the source

2. New research links unnecessary knee scans to avoidable surgery

Knee CT scans in Australia have jumped 83% in five years. That's quite a growth curve for a condition the guidelines have said for years doesn't need routine imaging.

The Australian Commission on Safety and Quality in Health Care's Atlas Focus Report: Osteoarthritis of the Knee also found knee ultrasounds rose 26% in people aged 45 and over in the five years to 2023-24. GPs requested more than 90% of them.

The likely culprit is a familiar one. In 2018 Medicare restricted GP-requested knee MRIs for patients 50 and over. Commission medical advisor and practising GP Dr Phoebe Holdenson Kimura says it's "possible that has contributed to the increase in the rates of CT and ultrasound as alternatives to MRI." Close the front door and the scans come in through the side window.

Rheumatologist Professor David Hunter is more worried about what happens after the scan. Degenerative meniscal lesions are common in older adults, and once a report lists them, further investigations, specialist referrals and inappropriate arthroscopy tend to follow. "When the patient sees that scan, they see a war zone of a report, and it's very hard for them to unsee that report," he says.

Knee arthroscopy hospitalisations have halved over the past decade, so the surgery message has landed. The imaging message hasn't.

The Commission names patient expectations, time pressure, fear of missing pathology and low confidence in clinical diagnosis as the drivers. That's a fair description of most afternoon clinics.

The takeaway: Before you reach for the request form, ask what the patient has already read or expects. Then walk them through how you've ruled out significant trauma, infection, inflammatory disease and true mechanical locking. Holdenson Kimura finds most patients are comfortable skipping the scan once they understand it won't change their management. The Commission's updated Osteoarthritis of the Knee Clinical Care Standard is worth a look this week.

Read the source

3. Stopping statins noninferior to continuing in older adults without CVD

"Do I still need these tablets?" now has an NEJM paper behind the answer, at least for some of your older patients.

The study was published online on 7 November to coincide with the American Heart Association Scientific Sessions in Chicago. It found that stopping primary-prevention statins in older adults without a history of cardiovascular disease was noninferior to continuing them. In plain terms, it's generally safe.

The summary we have skips the age cut-off, follow-up and event rates. It's also overseas evidence, with no word yet on Australian guidelines.

Expect it at medication reviews anyway, because patients read headlines faster than journals.

The takeaway: Read the full paper before your next older primary-prevention patient asks, and check who was enrolled. Anyone with established CVD is outside this one.

Read the source

Also noted

Get tomorrow's issue by email at 6:30am.